Author:
Zhu Dalong,Gan Shenglian,Liu Yu,Ma Jianhua,Dong Xiaolin,Song Weihong,Zeng Jiao'e,Wang Guixia,Zhao Wenjuan,Zhang Qiu,Li Yukun,Fang Hui,Lv Xiaofeng,Shi Yongquan,Tian Haoming,Ji Linong,Gao Xin,Zhang Lihui,Bao Yuqian,Lei Minxiang,Li Ling,Zeng Longyi,Li Xiaoying,Hou Xinghua,Zhao Yu,Hu Tianxin,Ge Xiaoyun,Zhao Guiyu,Li Yongguo,Zhang Yi,Chen Li
Funder
National Major Scientific and Technological Special Project for Significant New Drugs Development
Shanghai Science and Technology Innovation Action Project
Shanghai Pudong District Science and Technology Innovation Action Project
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference25 articles.
1. Defining and characterizing the progression of type 2 diabetes;Fonseca;Diabetes Care,2009
2. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes;Meier;Diabetes Care,2013
3. Pharmacotherapy of type 2 diabetes: an update;Upadhyay;Metabolism,2017
4. R&D strategies for type 2 diabetes: elucidate the underlying pathology and improve the impaired organ functions;Li;Prog Pharm Sci,2016
5. Investigational insulin secretagogues for type 2 diabetes;Scheen;Expert Opin Investig Drugs,2016